BOISE — Attorney General Raúl Labrador urges consumers to check their eligibility for compensation for certain generic drug purchases as Idaho has joined 50 states and territories in seeking preliminary approval for a $39.1 million settlement with generic drug manufacturer Apotex over conspiracy to inflate prices and limit competition.
Last fall, the multistate coalition announced the settlement in principle with Apotex along with a $10 million settlement with Heritage Pharmaceuticals. At the time of that announcement, the settlement with Apotex was conditioned on the signatures of all necessary states and territories. Those signatures have been obtained, and the coalition has filed the settlement in the U.S. District Court for the District of Connecticut in Hartford.
If you purchased a generic prescription drug between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (Toll-Free), email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com. This website includes a list of generic drugs involved in these settlements.
Attorney General Labrador stated, “When companies conspire to fix prices, real people pay the price—especially Idaho families who rely on affordable prescription drugs. I encourage every Idahoan who purchased generic medications during the covered period to review their eligibility and seek compensation if you qualify. Our office will continue to defend the integrity of the market and ensure Idahoans are protected from corporate misconduct.”
The settlement agreements resolve allegations that both Apotex and Heritage engaged in widespread, long-running conspiracies to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade with regard to numerous generic prescription drugs. As part of the settlement agreements, both Apotex and Heritage have agreed to cooperate in the ongoing multistate litigations against numerous other corporate defendants and individual executives. Both companies have further agreed to injunctive relief to prevent future misconduct and to a series of internal reforms to ensure fair competition and compliance with antitrust laws.